Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species

Read full text Summarise with VIRAT
Authors: Ammar A. Khan, Ehab A. Salama, Mohamed N. Seleem
Cited by: 0
References: 65

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Aspergillosis is a life-threatening fungal infection that primarily affects the lungs of immunocompromised individuals, including those living with human immunodeficiency virus (HIV), and is associated with mortality rates exceeding 50%. The infection is predominantly caused by Aspergillus fumigatus, a pathogen that has become increasingly difficult to treat due to the emergence of azole-resistant strains. Although azoles have traditionally served as first-line antifungals, the rise in resistance has necessitated broader use of amphotericin B (AmB), a polyene agent whose clinical utility is limited by its considerable toxicity. To address this therapeutic challenge, we screened a library of 618 antiviral compounds to identify agents that could synergize with AmB and enhance its antifungal efficacy. An initial screen identified 18 compounds that enhanced the antifungal activity of AmB. From this hit set, we prioritized the two FDA-approved HIV drugs, cobicistat and elvitegravir, as promising lead candidates. When combined with AmB, both compounds exhibited potent synergistic activity against A. fumigatus and other clinically relevant Aspergillus species, with FICI values

Fields of Study & Subjects

Antifungal resistance and susceptibility Fungal Plant Pathogen Control Ocular Infections and Treatments

Publication details

Journal / source
PLoS ONE
Volume
21
Issue
3
Pages
e0344286–e0344286
Publication date
25 March 2026
Language
EN